SLAMF7-directed Immunostimulatory Antibody [EPC]

5171 reported adverse events

Drugs of this class: ELOTUZUMAB

These side effects are most commonly reported by patients taking drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class:

# Side effect Count
0 PLASMA CELL MYELOMA 576
1 PNEUMONIA 304
2 DEATH 298
3 MALIGNANT NEOPLASM PROGRESSION 254
4 FATIGUE 236
5 DIARRHOEA 231
6 PYREXIA 221
7 DRUG INEFFECTIVE 204
8 NEUTROPENIA 194
9 ANAEMIA 173
See all common reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]

Drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PARAPROTEINAEMIA 11 0.0355
1 PLASMA CELL MYELOMA REFRACTORY 47 0.0351
2 FEBRILE INFECTION 27 0.0229
3 PLASMA CELL LEUKAEMIA 13 0.0217
4 CAMPYLOBACTER GASTROENTERITIS 12 0.0202
5 PNEUMOCOCCAL SEPSIS 13 0.0198
6 PLASMA CELL MYELOMA 576 0.0147
7 PLASMA CELL MYELOMA RECURRENT 40 0.0123
8 PNEUMONIA PNEUMOCOCCAL 14 0.0094
9 KERATOPATHY 14 0.0088
See all enriched reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]